Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.

Trial Details

NCT ID
NCT06533579
Phase
PHASE1 / PHASE2
Sponsor
Vironexis Biotherapeutics Inc.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Dose Level 1, VNX-101
  • Dose Level 2, VNX-101
  • Dose Level 3, VNX-101
  • Dose Level 4, VNX-101
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Los Angeles, California, United States|34.05223,-118.24368
  • Denver, Colorado, United States|39.73915,-104.9847
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Rochester, Minnesota, United States|44.02163,-92.4699

Key Eligibility Criteria

  • Age: Part 1: 18-90 years of age, Part 2: 13-90 years of age
  • Relapsed or refractory CD-19 positive leukemia or lymphoma as defined in the protocol
  • CD19-positive expression
  • AAV specified capsid total antibody \<1:400

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →